Outcome‐Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry

Background Immunosuppressive therapy (IST) is commonly used in cardiac sarcoidosis, but the strategy to guide it is unclear and its effectiveness uncertain. We assessed the association between IST, guided by clinical course and positron emission tomography, and clinical outcomes in cardiac sarcoidosis. Methods We compared 83 patients with cardiac sarcoidosis who received IST with 20 who declined therapy. IST was escalated for persistent symptoms and inflammation. Ventricular arrhythmia recurrence, ventricular pacing, New York Heart Association class, and left ventricular (LV) ejection fraction were assessed after 12 months. Death, LV assist device, and heart transplantation were assessed during a median follow‐up of 24.9 months. Results Sustained ventricular tachycardia recurred in 12% of patients with IST versus 20% of those without IST ( P =0.264). Within the IST group, New York Heart Association class and LV ejection fraction improved during 12 months ( P =0.011 and P =0.002), but the between‐group difference in New York Heart Association change was not significant ( P =0.490). Major adverse cardiovascular events occurred less frequently with IST (10.8% versus 40.0%, P =0.004). After adjustment for baseline LV ejection fraction, IST had a lower hazard of major adverse cardiovascular events (hazard ratio, 0.30 [95% CI, 0.11–0.80]; P =0.017), consistent among sensitivity analyses. Given only 17 events and baseline imbalance, residual confounding cannot be excluded and this is hypothesis‐generating. Conclusions In this observational registry, glucocorticoid‐based IST was associated with lower rates of death, heart transplantation, and LV assist device implantation. No significant between‐group difference was detected in sustained ventricular tachycardia recurrence, although the study was underpowered to exclude smaller differences. Because treatment was not randomized, these associations cannot establish causality.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-09-18
DOI
https://doi.org/10.1161/jaha.126.049395
Primary Topic
Sarcoidosis and Beryllium Toxicity Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Outcome‐Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry

Ingo Paetsch, Hans Ebbinghaus, Gerhard Hindricks, Laura Ueberham et al.
Journal of the American Heart Association
Sarcoidosis and Beryllium Toxicity Research
article

Outcome‐Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry

Ingo Paetsch, Hans Ebbinghaus, Gerhard Hindricks, Laura Ueberham, Cosima Jahnke, Sotirios Nedios, Konrad Latuscynski, Kerstin Bode, Borislav Dinov, Turid Franziska Ebbinghaus‐Holst, Joanna Jozwiak‐Nozdrzykowska
article en

Abstract

Background Immunosuppressive therapy (IST) is commonly used in cardiac sarcoidosis, but the strategy to guide it is unclear and its effectiveness uncertain. We assessed the association between IST, guided by clinical course and positron emission tomography, and clinical outcomes in cardiac sarcoidosis. Methods We compared 83 patients with cardiac sarcoidosis who received IST with 20 who declined therapy. IST was escalated for persistent symptoms and inflammation. Ventricular arrhythmia recurrence, ventricular pacing, New York Heart Association class, and left ventricular (LV) ejection fraction were assessed after 12 months. Death, LV assist device, and heart transplantation were assessed during a median follow‐up of 24.9 months. Results Sustained ventricular tachycardia recurred in 12% of patients with IST versus 20% of those without IST ( P =0.264). Within the IST group, New York Heart Association class and LV ejection fraction improved during 12 months ( P =0.011 and P =0.002), but the between‐group difference in New York Heart Association change was not significant ( P =0.490). Major adverse cardiovascular events occurred less frequently with IST (10.8% versus 40.0%, P =0.004). After adjustment for baseline LV ejection fraction, IST had a lower hazard of major adverse cardiovascular events (hazard ratio, 0.30 [95% CI, 0.11–0.80]; P =0.017), consistent among sensitivity analyses. Given only 17 events and baseline imbalance, residual confounding cannot be excluded and this is hypothesis‐generating. Conclusions In this observational registry, glucocorticoid‐based IST was associated with lower rates of death, heart transplantation, and LV assist device implantation. No significant between‐group difference was detected in sustained ventricular tachycardia recurrence, although the study was underpowered to exclude smaller differences. Because treatment was not randomized, these associations cannot establish causality.

Journal of the American Heart Association
Universitätsklinikum Gießen und Marburg (DE), Klinikum St. Georg (DE), Leipzig Heart Institute (DE), Helios Park-Klinikum Leipzig (DE), University Hospital Leipzig (DE), Charité - Universitätsmedizin Berlin (DE)
Good health and well-being
Openalex Percentile: Top 12%
Sarcoidosis and Beryllium Toxicity Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.